|
Re: Debt and 28 August
|
4
|
Resverlogix Corp.
|
Jul 29, 2017 12:59PM
|
|
Re: Debt and 28 August
|
3
|
Resverlogix Corp.
|
Jul 29, 2017 02:23PM
|
|
Re: Zenith new VP
|
2
|
Zenith Epigenetics
|
Jul 31, 2017 12:31AM
|
|
Re: Zenith new VP
|
2
|
Zenith Epigenetics
|
Jul 31, 2017 09:07AM
|
|
Re: Zenith new VP
|
|
Zenith Epigenetics
|
Jul 31, 2017 09:15PM
|
|
Re: Zenith new VP
|
1
|
Zenith Epigenetics
|
Aug 02, 2017 01:05AM
|
|
Re: Chemical probes targeting epigenetic proteins: Applications beyond oncology
|
2
|
Resverlogix Corp.
|
Aug 05, 2017 02:25AM
|
|
Re: Seeking Alpha articles
|
5
|
Resverlogix Corp.
|
Aug 05, 2017 01:34PM
|
|
Re: Chemical probes targeting epigenetic proteins: Applications beyond oncology
|
6
|
Resverlogix Corp.
|
Aug 05, 2017 01:46PM
|
|
Re: Seeking Alpha articles
|
3
|
Resverlogix Corp.
|
Aug 05, 2017 04:32PM
|
|
Re: Veterinary Applications?
|
5
|
Zenith Epigenetics
|
Aug 06, 2017 10:26PM
|
|
Re: Q3 Events updated
|
4
|
Resverlogix Corp.
|
Aug 10, 2017 11:47PM
|
|
Re: I think I actually prefer silence....
|
3
|
Resverlogix Corp.
|
Aug 12, 2017 01:47AM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
5
|
Zenith Epigenetics
|
Aug 12, 2017 05:53PM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
7
|
Zenith Epigenetics
|
Aug 13, 2017 06:57PM
|
|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
3
|
Resverlogix Corp.
|
Aug 15, 2017 10:11AM
|
|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
8
|
Resverlogix Corp.
|
Aug 15, 2017 03:58PM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
6
|
Zenith Epigenetics
|
Aug 17, 2017 02:41AM
|
|
Re: Three Nature Medicine Articles on BET inhibitors and Prostate Cancer
|
3
|
Zenith Epigenetics
|
Aug 17, 2017 02:43AM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
5
|
Zenith Epigenetics
|
Aug 17, 2017 02:37PM
|
